GoodRx (GDRX) Reports Q2 Earnings: What Key Metrics Have to Say

Core Insights - GoodRx Holdings, Inc. reported revenue of $200.61 million for the quarter ended June 2024, reflecting a year-over-year increase of 5.8% [1] - The earnings per share (EPS) for the same period was $0.08, compared to $0.07 a year ago, with an EPS surprise of -11.11% against a consensus estimate of $0.09 [1] Revenue Breakdown - Revenue from prescription transactions was $146.70 million, exceeding the estimated $146.29 million, marking a year-over-year increase of 7.5% [5] - Revenue from other sources was $5.40 million, slightly above the estimated $5.35 million, representing a year-over-year change of 10.2% [6] - Revenue from Pharma Manufacturer Solutions was $26.50 million, below the estimated $27.48 million, but still showing a year-over-year increase of 9.1% [7] - Subscription revenue was reported at $22 million, surpassing the estimated $21.17 million, but reflecting a year-over-year decline of 8% [8] Consumer Metrics - Monthly Active Consumers were reported at 7 million, matching the average estimate from three analysts [3] - Total subscribers were reported at 696, falling short of the two-analyst average estimate of 763 [4] Stock Performance - GoodRx shares have returned +7.8% over the past month, contrasting with a -6.5% change in the Zacks S&P 500 composite [8] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [8]